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A B S T R A C T
Inflammation is an obligatory marker of arterial disease, both stemming from the inflammatory activity of
cholesterol itself and from well-established molecular mechanisms. Raised progenitor cell recruitment after
major events and clonal hematopoiesis related mechanisms have provided an improved understanding of factors
regulating inflammatory phenomena. Trials with inflammation antagonists have led to an extensive evaluation
of biomarkers such as the high sensitivity C reactive protein (hsCRP), not exerting a causative role, but fre-
quently indicative of the individual cardiovascular (CV) risk. Aim of this review is to provide indication on the
anti-inflammatory profile of agents of general use in CV prevention, i.e. affecting lipids, blood pressure, diabetes
as well nutraceuticals such as n-3 fatty acids. A crucial issue in the evaluation of the benefit of the anti-in-
flammatory activity is the frequent discordance between a beneficial activity on a major risk factor and asso-
ciated changes of hsCRP, as in the case of statins vs PCSK9 antagonists. In hypertension, angiotensin converting
enzyme inhibitors exert an optimal anti-inflammatory activity, vs the case of sartans. The remarkable preventive
activity of SLGT-2 inhibitors in heart failure is not associated with a clear anti-inflammatory mechanism. Finally,
icosapent ethyl has been shown to reduce the CV risk in hypertriglyceridemia, with a 27 % reduction of hsCRP.
The inflammation-based approach to arterial disease has considerably gained from an improved understanding
of the clinical diagnostic strategy and from a better knowledge on the mode of action of numerous agents,
including nutraceuticals.
1. Introduction
Inflammation has been historically considered as an obligatory
marker of arterial disease. Cholesterol itself is an inflammatory med-
iator, being a crystalline product [1] and, by its physical presence,
activating NLRP3 (NACHT-, LRR- and pyrin domain-containing 3), a
general mediator of arterial tissue inflammation [2]. NLRP3 nucleates
the assembly of an inflammasome, leading to caspase 1-mediated ac-
tivation of the interleukin-1β (IL-1β) family of cytokines, thus inducing
an inflammatory pyroptotic cell death [3]. This molecular mechanism is
the final development of the seminal idea by Ross and Glomset, who
postulated endothelial injury as the inducer of cell proliferation and
expansion of smooth muscle cells (SMCs) [4,5]. The association be-
tween local inflammation, elevated levels of low-density lipoproteins
(LDL) and noxious life habits brought forward the concept of structural
lipoprotein changes allowing aggregation and/or oxidation [6]. The
presently established role of enhanced myelopoiesis in the development
of arterial inflammatory changes and the identification of newer med-
iators from both inflammatory and immune systems can provide novel
mechanisms underlying the development of arterial disease.
As a lipid-driven inflammatory disease, a balance of proin-
flammatory and inflammation-resolving mechanisms is responsible for
the final outcomes [7]. While bone marrow (BM) and spleen were not
considered to play a significant role in atheroma formation, it is now
well established that BM is responsible for the enhanced myelopoiesis,
allowing recruitment of inflammatory cells, particularly monocytes, to
the arterial intima [8,9]. The rise of hematopoietic and progenitor cells
(HSPCs) occurring after myocardial infarction (MI) [10] can well ex-
plain the increased growth of plaques and the associated higher pro-
tease activity. Clonal hematopoiesis (CH), in addition to eliciting effects
through inflammatory mediators, reduces the epigenetic modifier en-
zyme ten-eleven translocation 2 (TET2) raising atherosclerotic risk
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[11]. TET2 deficient cells, when clonally expanded, markedly increase
plaque size and NLRP3 inflammasome mediated IL-1β secretion [12].
Further, toll-like receptor 4 (TLR4) [13] by interacting with myeloid
differentiation factor-88 (MyD88) can lead to cellular signaling, re-
sulting in hematopoietic and stromal cell development [14]. Hyperch-
olesterolemia causes HSPCs to proliferate, leading to leukocytosis and
enhanced atherosclerosis both in animal models and humans [15]. As
very recently described by Gu and colleagues [16], in the zebrafish
deficient in the cholesterol efflux pathway mediated by apolipoprotein
binding protein 2 there is a loss of capacity of HDL to accept cholesterol
and increased hematopoiesis by way of NOTCH signaling, hypothe-
sizing a cholesterol metabolic pathway controlling emergence of
HSPCs. These findings have postulated a role of the NOTCH family in
the expansion of hematopoietic stem cells [17]. Further, the reported
novel roles of apolipoprotein binding protein 2 and of the sterol reg-
ulatory element-binding protein 2 (SREBP2) [17] have clearly indicated
the presence of SREBP2 binding DNA sequences in Notch as well as in
genes regulating cholesterol synthesis, most likely relevant in adult
hematopoiesis [16].
Hematopoietic cells are also characterized by the Akt (protein
kinase B) pathway, i.e. a serine/threonine-specific protein kinase
playing multiple roles in processes, such as glucose metabolism,
apoptosis, cell migration and proliferation, with three isoforms,
Akt1, Akt2 and Akt3. Loss of Akt1 in apo E−/− mice leads to severe
atherosclerosis [18], whereas loss of Akt1 and Akt2 in hematopoietic
cells (Akt3only) provides arterial protection. The presence of only the
Akt1 isoform is detrimental for the viability of monocytes/macro-
phages, eventually leading to the development of smaller athero-
sclerotic lesions.
LDL-associated inflammatory changes may thus be linked to en-
hanced hematopoiesis although the role of TET2 mutations has not
been confirmed in all studies [19] but also to direct activities such as: a)
enhanced cholesterol crystal deposition, raising the vascular in-
flammasome NLRP3; b) rise of different T lymphocyte subtypes leading
to plaque proliferation and potential rupture [20]; c) development of
tissue inflammatory changes, mainly linked to raised cytokines and
hsCRP.
A link between the first two mechanisms, i.e. direct inflammatory
effects and T cell proliferation, has been provided by the identification
of a novel regulator i.e. the NLRC5 (NLRF family CARD Domain
Containing 5) previously known as a major regulator of innate im-
munity [21]. NLRC5 has an essential role in determining vascular in-
timal hyperplasia [22] and NLRC5 knock-out (Nlrc5−/) mice exhibit
more severe intimal hyperplasia compared to wild-type mice after
carotid ligation. NLRC5 deficiency leads to increased proliferation and
migration of human vascular SMC. NLRC5 appears to bind to peroxi-
some proliferator-activated receptor (PPAR)γ inhibiting dedifferentia-
tion of human SMC. These damaging mechanisms are antagonized by
the PPARγ agonist pioglitazone [22].
Recently Lee et al [23] investigated the contribution of SMC to the
foam cell abundance in apo E−/− mice. By evaluating expression of
leukocyte specific markers, non-leukocyte foam cells increased from 37
% in 27-week-old to 75 % in 57-week-old male apo E-/- mice fed a chow
diet compared to about 70 % in male and female apo E-/- after 6 weeks
on a Western diet. This finding provides an important link between the
observation of foam cells in human and mouse atheromas, suggesting
an upregulated role of SMCs in foam cell formation [24]. It indicates the
need for more advanced lineage tracing models on mice and proteomic
evaluations in man, in order to accurately define the origin and func-
tions of cell types in lesions and to design improved therapeutic ap-
proaches to enhance plaque stability.
A novel and poorly explored immune-related area of vascular in-
flammation is that of serum factor H, a regulator of the alternative
complement pathway [25]. The central function of factor H related
protein 1 (FHR1) has remained unclear. FHR1 competes with factor H
in the regulation of its inhibitory activity [26]. Studies on the role of
factor H and FHR1 in cytoplasmic antibody associated vasculitis and
atherosclerosis have provided exciting openings on the role of FHR1 in
the activation of monocyte inflammasomes. FHR1 appears to bind ne-
crotic cells in plaques, in addition inducing inflammasome NLRP3 in
blood derived monocytes that subsequently secrete interleukin (IL)1β,
tumor necrosis factor (TNF)α, IL-18 and IL-6 [27]. FHR1 concentrations
in patients with antibody-associated vasculitis are associated with le-
vels of inflammation and progressive disease. This unexpected role for
FHR1 during inflammation may explain the protection by FHR1 defi-
ciency, indicating it as potential target for treatment of arterial in-
flammatory diseases [27].
Finally, a potential regulator of the proinflammatory signaling from
neutrophils is the dimeric S100 A8/A9, a proinflammatory alarmin,
highly expressed in neutrophils and rapidly released into the circulation
after myocardial ischemia [28]. This potent activator of the receptor of
advanced glycation end products [29] was found to be associated with
reduced ventricular ejection fraction one-year after the MI [30], with a
raised incidence of hospitalizations from heart failure.
In view of the diversified tissue responses to inflammatory stimuli
and the need for a better understanding of diagnostic procedures and
possible therapeutic approaches, the aim of this review article is
manifold. It will examine present day evidence of the most appropriate
diagnostic approaches and will evaluate in detail the pharmacological
strategies, examining the possible anti-inflammatory profile of drugs of
major use in cardiovascular prevention. This in-depth scrutiny will lead
at times to apparent discrepancies between efficacy on a major ther-
apeutic target and presence or absence of anti-inflammatory activity.
These observations may be of crucial value in the selection of the most
appropriate therapeutic agent.
2. Clinical evaluation of inflammation-associated cardiovascular
risk
The need for an easier access to the evaluation of cardiovascular
(CV) risk associated to inflammation has led to the wide use of C-re-
active protein (CRP), a mediator well known in the monitoring of sys-
temic inflammatory diseases, such as rheumatoid arthritis and other
articular disorders. CRP is a member of the short pentraxin family,
expression being stimulated by proinflammatory cytokines, i.e. in par-
ticular IL-6, but also IL-1β, TNFα and others [31]. CRP binds microbial
polysaccharides and ligands on damaged cells. This leads to activation
of the classical complement mediated pathway, thus removing da-
maged or apoptotic cells, in turn activating monocytes [32].
While there is general agreement that CRP is a relevant risk bio-
marker for CVD [33,34], there has been no consensus on a causative
role. Mendelian randomization studies failed to prove a causal link
between genetic variants of CRP affecting protein level and risk of
coronary heart disease [35], in contrast to the case of IL-6 [36], with,
however, impractical diagnostic application due to a short half-life and
circadian variations [37]. The same conclusion applies to IL-1β, since
there is no available technology allowing a reliable measurement. The
difficulty in determining these cytokines contrasts with the commer-
cially robust and standardized high-sensitivity (hs)CRP immunoassay.
The association of plaque morphology/tendency to rupture with
hsCRP levels has been evaluated by appropriate studies [38]. The
prognostic value of hsCRP in post-acute coronary syndrome (ACS) pa-
tients on optimal medical treatment was found to be weak [39]. A
higher sensitivity was found in a cross-sectional study [40], indicating
significant correlations with the dynamic changes in plaque structure.
In the small IBIS Study a reduction of necrotic core volume with lower
hsCRP, not LDL-C, was described [41]. In a more extensive serial in-
travascular imaging, after 12 months of rosuvastatin treatment, changes
of hsCRP showed highly significant positive correlations with necrotic
core and dense calcium volumes and negative correlations with fibrous
and fibrofatty plaque volumes, not with LDL-cholesterol changes [42].
There is thus as present a high interest in evaluating risk of CV
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disease (CVD) and other diseases in individuals with low LDL-C [43], a
frequent finding in coronary patients, associated with an increased risk
of all-cause mortality [44]. Low LDL-C may be a chance finding in
random series of individuals or it may be dependent upon mutations in
proprotein convertase subtilisin/kexin type 9 (PCSK9), angiopoietin-
like 3, microsomal triglyceride transfer protein or apolipoprotein (apo)
B [45]. In order to assess the critical value of LDL-C vs hsCRP, a crucial
study was that by Penson et al on Reasons for Geographical and Racial
Differences in Stroke (REGARDS) [46]. In this, the relationship between
low LDL-C (< 70mg/dL) compared to> 70mg/dl and hsCRP<2
compared with ≥2mg/L was evaluated. The Authors concluded that
participants with high LDL-C and low hsCRP have a lower risk of stroke,
CHD and CHD deaths compared to those in the same LDL-C category
but with high hsCRP. Participants with high hsCRP (≥ 2mg/L) and low
LDL-C (< 70mg/dL) did not show any additional risk reduction but a
significant rise of all-cause mortality [46].
These findings are in line with those more recently provided by
Guedenay et al evaluating residual inflammatory risk (RIR) in 3,013
patients undergoing percutaneous interventions with low baseline LDL-
C (≤ 70mg/dL) [47] and serial hsCRP assessments. They were char-
acterized as persistent low RIR, attenuated RIR (first high then low
hsCRP), increased RIR (first low then high hsCRP), or persistent high
RIR. There was a stepwise raised incidence rate of major adverse car-
diac and cerebrovascular accidents in these four risk categories within
one year of the second hsCRP measurement.
3. Drug approaches to the inflammatory cardiovascular residual
risk
A number of drug approaches have been guided by knowledge of
the inflammatory basis of CVD (Table 1). The CV preventive activity of
the most widely used inhibitor of cyclooxygenase (COX)-1 antagonist,
aspirin, has not been recently supported by a number of large controlled
intervention studies [48,49], although possibly the drug may be effec-
tive in individuals homozygous for the soluble guanylate cyclase (sGC)
gene variant GUCY1A3 risk(G) allele [50]. Selective COX-2 inhibitors
have led to CV harm, in particular rofecoxib, although the later large
PRECISION study comparing celecoxib with ibuprofen and naproxen in
over 27,000 subjects with arthritis did not identify a clear CV harm
[51]. In a follow-up study celecoxib proved actually safer than ibu-
profen and naproxen when given with aspirin [52] but there was no
evidence of CV benefit.
Aside from the COX-inhibitors, agents modulating pathways in
downstream response to injury, i.e. secretory and lipoprotein associated
phospholipase A2 [53], P-selectin [54] and the IL-1 β selective inhibitor
anakinra [55], all failed to provide evidence of potential activity on CV
endpoints.
The CANTOS trial with the anti-IL-1-β monoclonal antibody cana-
kinumab [56], enrolled patients with previous MI and hsCRP ≥ 2mg/L
and provided a proof-of-concept for the hypothesis of residual in-
flammatory risk. Canakinumab reduced hsCRP by 35 % and did not
affect, at any dose, LDL-C, HDL-C and TG levels [57]. After a median
follow-up of 3.7 years, doses of 150 and 300mg were superior to pla-
cebo in meeting the primary endpoint, i.e. a composite of nonfatal MI,
nonfatal stroke, or CV death. The hazard ratio (HR)=0.85 (95 %CI:
0.74-0.98), translated to a number-needed to treat (NNT) of 156 for
1 year to prevent an event; NNT becomes 189 when the analysis is
confined to changes in MI (HR: 0.76). CV deaths were not significantly
reduced (HR: 0.88) [58]. No reduction in the incidence of new-onset
diabetes was found. Canakinumab reduced MACE rates to a similar
extent in patients with or without diabetes [59] and was associated
with a significant reduction in deaths from lung cancer [60]. Deaths
from infection were instead significantly raised.
Among patients on canakinumab, those achieving on-treatment
hsCRP ≤ 2mg/L had a higher benefit in terms of reduction of major CV
events (HR: 0.75; 95 % CI: 0.66-0.85), CV mortality (HR: 0.69; 95 % CI:
0.56-0.85) and all-cause mortality (HR: 0.69; 95 % CI: 0.58-0.81) re-
gardless of canakinumab dose (Fig. 1) [61]. Reaching this hsCRP
threshold translated into a 5-year NNT estimate of 16 for MI, stroke,
coronary revascularization or all-cause death. For participants who did
not achieve on-treatment hsCRP<2mg/dL the 5-year NNT estimate
was 57 [61]. Among chronic kidney disease patients, canakinumab
reduced the risk of MACEs by 18 % with the highest benefit for those
achieving on-treatment hsCRP levels below 2mg/L (-32 %) [62]. Ca-
nakinumab reduced in a dose dependent manner the composite of
hospitalizations for heart failure or heart failure-related mortality:
HR=1.00 (50mg, reference value), 0.88 (150mg) and 0.78 (300mg)
[62].
A further trial investigating efficacy of anti-inflammatory treat-
ments in coronary patients was the Cardiovascular Inflammation
Reduction Trial (CIRT), designed to evaluate the effects of low dose
methotrexate (15–20mg per week) vs placebo. Patients had to have, in
addition to prior MI or multivessel coronary disease, either type 2
diabetes or the metabolic syndrome. The trial was stopped since
methotrexate did not result in the lowering of IL-1β, IL-6 or hsCRP vs
Table 1
Percentage changes of hsCRP upon treatments with Canakinumab, Metotrexate and Colchicine.
Clinical study hsCRP (mg/L) in the active group Primary Endpoint
pre post
Canakinumab [57] CANTOS* 4.25 2.10 HR 0.85; 95 % CI 0.74–0.98; p= 0.021
Methotrexate [63] CIRT** 1.45 (0.73, 3.40) 1.56 (0.77, 3.53) HR 1.01; 95 % CI 0.82–1.25; p= 0.91
Colchicine [68] COLCOT*** 4.27 (2.12, 7.22) 1.37 (0.75, 2.13) HR 0.77; 95 % CI, 0.61 to 0.96; p= 0.02
CANTOS, Canakinumab Antiinflammatory Thrombosis Outcome Study; CIRT, Cardiovascular Inflammation Reduction Trial; COLCOT, Colchicine Cardiovascular
Outcomes Trial. hsCRP, high-sensitivity C-reactive protein.
* values are referred to all doses (50mg, 150mg and 300mg). Post= after 48 months.
** Pre= from enrollment; Post= 8 months post randomization.
*** Pre= at randomization; Post= 6 months post randomization.
Fig. 1. A secondary analysis of CANTOS study showed that patients achieving
on-treatment hsCRP concentrations, at 3 months, ≤ 2mg/L had a higher
benefit in terms of reduction in major CV events, CV mortality and all-cause
mortality. The dash represents the reference value. CV, cardiovascular; MI,
myocardial infarction (reproduced with permission of Taylor & Francis) [76].
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placebo. The primary endpoint occurred in 201 patients in the meth-
otrexate and 207 in the placebo group (HR 0.96, 95 % CI 0.79–1.16).
Methotrexate treatment was associated with raised liver enzymes, re-
duction in leukocytes and hematocrit and a higher incidence of non-
basal cell skin cancer vs placebo [63]. The different patient selection
may explain the divergent results: in the CANTOS study patients were
selected based on elevated hsCRP levels, whereas CIRT included pa-
tients with relatively normal inflammatory biomarkers
(hsCRP=1.6mg/L), poorly modified by treatment [64].
Colchicine, of general use in the treatment of gouty attacks and
pericarditis, by inhibiting neutrophil motility and with marked anti-
inflammatory effects, particularly in reducing local cytokine production
[65], and improving endothelial function [66] was the object of a large
outcome trial, the Colchicine Cardiovascular Outcomes Trial
(COLCOT). This examined the effects of low dose colchicine (0.5 mg/
day) or placebo on CV events in 4,745 patients with ACS on optimal
medical treatment, randomized within 30 days of the event [67]. The
primary end-point occurred in 5.5 % of patients given colchicine vs 7.5
% in the placebo group (HR 0.77; 95 % CI 0.62-0.96) [68]. The effect
was predominantly driven by lower risk of angina and stroke, without a
significant effect on death from CV causes or MI incidence. No changes
in hsCRP were detected, thus casting doubt on the postulated anti-in-
flammatory protective mechanism [69]. A number of other inflamma-
tion antagonists including those targeting L-6 or TNF-α have been also
tested without success. TNF-α (etanercept) and IL-6 blockade (tocilu-
zumab) tend to increase pro-atherogenic apo B containing lipoproteins
[70,71].
A protective role of HDL in reducing plaque inflammation has been
finally described recently [72] in diabetic mice, reporting a promoted
atherosclerosis regression by raising HDL levels, a benefit linked to
suppressed hyperglycemia induced hematopoiesis, monocytosis and
neutrophilia. The improvement in cholesterol efflux from bone marrow
progenitors led to a suppression of proliferation as well as to polar-
ization of plaque macrophages to the atherosclerosis-resolving M2.
4. Lipid lowering agents and inflammation
4.1. Statins
The beneficial effect of statins on coronary events is generally as-
sumed to be linked to their hypocholesterolemic properties [73]. Since
mevalonic acid is the precursor of numerous metabolites, inhibition of
HMG-CoA reductase potentially results in pleiotropic effects [74].
However, statins can decrease the number of LDL particles infiltrating
the vessel wall and thus potentially reducing CRP. Statins do indeed
display significant anti-inflammatory effects and this has led to some
non-lipid indications, e.g. the treatment of periodontal inflammation
associated with reduced carotid inflammation [75].
The role of hsCRP reduction in the large number of statin trials has
been the object of a prior review article [76] and data are thus sum-
marized in Table 2. The early CARE (Cholesterol and Recurrent Events)
trial showed that the relative CV risk reduction was larger in patients
with elevated hsCRP [77]. This observation was confirmed in other
studies, such as the Air Force/Texas Coronary Atherosclerosis Preven-
tion Study (AFCAPS/TexCAPS), REVERSAL (Reversal of Atherosclerosis
with Aggressive Lipid Lowering), PROVE IT–TIMI 22 (Pravastatin or
Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myo-
cardial Infarction 22) and A to Z (Aggrastat-to-Zocor) [78–81]. In all
these, the largest benefit was found in patients achieving LDL-
C< 70mg/dL and hsCRP<2mg/L [82]. This was confirmed in the
primary prevention JUPITER trial on 18,000 patients with median LDL-
C 108mg/dL and elevated hsCRP (> 2.0mg/L) [83], where the largest
reduction in CV events (-65 %), occurred upon achieving both LDL-
C< 70mg/dL and hsCRP<2mg/dL [84].
4.2. Ezetimibe
Ezetimibe, an inhibitor of the cholesterol transport protein NPC1-
like 1, reduces intestinal cholesterol absorption [85]. When added to
statins, it leads to an incremental lowering of LDL-C levels and im-
proved cardiovascular outcomes [86].
In a study on rabbits on a high fat diet and atherosclerosis, ezeti-
mibe led to both reduced progression of atheromas and plaque stabi-
lization. CRP levels were significantly reduced with no further reduc-
tion occurring by the addition of simvastatin [87]. Clinical studies did
not fully confirm this conclusion, i.e. a pooled analysis of trials in hy-
percholesterolemic patients showed no significant hsCRP changes.
Conversely, when ezetimibe was added to baseline statin therapy, a -10
% reduction of hsCRP was observed [88]. In the recent IMPROVE-IT
trial, adding ezetimibe to simvastatin gave a further 20 % and 14 %
reduction of LDL-C and hsCRP, respectively [89]. In chronic kidney
disease patients (SHARP trial), the combination simvastatin/ezetimibe
resulted in a 35 % reduction of LDL-C vs placebo and a 21 % reduction
of hsCRP [90] (Table 2).
4.3. Bempedoic acid
This prodrug, targeting ATP-citrate lyase (ACL), is primarily re-
sponsible for the production of extra-mitochondrial acetyl-CoA [91],
the carbon precursor for cholesterol and fatty acid biosynthesis. Bem-
pedoic acid is metabolized to the active form only in the liver, not in
muscle.
Phase 3 studies have indicated a stable LDL-C reduction in the range
of 25–35 %, additional to that of statins, with minimal muscular side
effects. Clinical studies have consistently shown a marked hsCRP low-
ering activity, the highest efficacy being reported in diabetics [92], i.e.
-41 % (median changes). In the CLEAR Tranquility trial on statin in-
tolerant patients, bempedoic acid (180mg) added to background lipid-
modifying therapy reduced LDL-C and hsCRP by -28.5 % and -34.6 %,
respectively (vs placebo) [93]. In the CLEAR Harmony trial, enrolling
patients with LDL-C of at least 70mg/dL despite maximum tolerated
statin therapy, bempedoic acid treatment resulted in greater LDL-C
lowering vs placebo at week 12 (difference, -18.1 %), 24 (difference,
-16.1 %) and 52 (difference, -13.6 %). Relative to hsCRP, the absolute
difference was -25 %, -19.1 % and -16.2 % at weeks 12, 24, and 52
respectively [94] (Table 2).
In the CLEAR Wisdom trial, enrolling patients with atherosclerotic
cardiovascular diseases (ASCVD), heterozygous familial hypercholes-
terolemia, or both, on optimal statin treatment, bempedoic acid was
superior to placebo in reducing hsCRP at weeks 12 and 24 with an
absolute difference of -8.7 % and -21.3 %, respectively. At week 52, the
difference between groups was not statistically significant (-7.6 %;
p=0.10). At enrolment, hsCRP levels were 1.61 (mg/L) in the bem-
pedoic and 1.88 (mg/L) in the placebo group [95] (Table 2).
The CLEAR Serenity trial evaluated the LDL lowering activity and
tolerability of bempedoic acid in statin intolerant patients with ASCVD
and inadequately controlled LDL-C over a period of 24 weeks. After a
12-week treatment, in patients on very low dose statin, other lipid-
modifying therapy or no therapy, hsCRP fell by 28 % (vs placebo). This
effect was maintained at week 24 (-27.1 %) [96].
Combination of bempedoic acid with ezetimibe dramatically re-
duced LDL-C up to -41 %. Bempedoic acid plus ezetimibe reduced
hsCRP by 35.1 % compared to a rise of 21.6 % in the placebo group and
an 8.2 % reduction with ezetimibe, given as a monotherapy [97]. The
combination therapy was not superior to bempedoic acid alone, prob-
ably due to the considerable hsCRP lowering achieved in monotherapy
(-31.9 %). In each treatment group, baseline levels of hsCRP were
3.1 mg/L (bempedoic acid+ ezetimibe), 2.9mg/L (bempedoic acid),
2.8 mg/L (ezetimibe), and 3.0mg/L (placebo) [97,98] (Table 2).
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4.4. Nicotinic acid
Nicotinic acid (niacin or vitamin B3), at pharmacological doses, i.e.
about 1–2 g/day exerts a powerful antilipolytic activity, reducing free
fatty acid (FFA) release from the adipose tissue to the liver, where
triglycerides (TG) re-synthesis occurs [99]. Some Authors believe that
nicotinic acid, similar to fibrates, may exert a moderate stimulation of
peroxisomal proliferation as a PPARα agonist [100]. In this way nico-
tinic acid may activate lipoprotein lipase reducing TG, to a lesser extent
LDL-C, and raising HDL-C levels [101].
The profile of nicotinic acid, particularly the significant positive
impact on HDL-C levels, has led to large placebo controlled studies in
ASCVD patients [102,103] given extended release nicotinic acid. These
studies did not result in a significant reduction of major coronary
events. In metabolic syndrome [104], nicotinic acid reduced hsCRP by
-40 % (from 2.7 ± 0.55mg/L to 1.7 ± 0.25mg/L), and similar, albeit
lesser reductions, were noted for TNF-α, Plasminogen activator in-
hibitor-1 (probably reflecting the reduction of TGs) and IL-7, not IL-6.
In a comparative evaluation of nicotinic acid and fenofibrate, the
former was more effective at lowering hsCRP, though fenofibrate led to
a more beneficial lipoprotein profile [105].
4.5. Fibrates
These activators of the PPARα system have not shown clear effects
on hsCRP. A 5-year treatment with fenofibrate significantly reduced
LDL-C (14.2 %) but not hsCRP (+ 0.8mg/L) [106], a finding similar to
the data described in a sub-analysis of the FIELD (Fenofibrate Inter-
vention and Event Lowering in Diabetes) trial in type 2 diabetics [107].
In patients with mixed dyslipidemia, rosuvastatin (40mg), rosuvastatin
(10mg) plus fenofibrate (200mg) or rosuvastatin (10mg) plus omega 3
(2 g) led to 53 %, 28 % and 23 % reductions in hsCRP, respectively, vs
baseline [108]. In patients with the metabolic syndrome, however, a
highly significant hsCRP reduction of 49.5 % was reported [109].
4.6. Proprotein convertase subtilisin/kexin 9 (PCSK9) antagonists
PCSK9 is a liver-secreted plasma protein that regulates the number
of cell-surface LDL receptors, thus inhibiting LDL uptake [110,111].
Two fully human mAbs, alirocumab and evolocumab, have been ap-
proved for human use in August 2015, whereas bococizumab has been
discontinued in November 2016 [112]. Other approaches to inhibit
PCSK9 are being developed, including small molecule inhibitors, anti-
sense oligonucleotides, RNA interference therapies (inclisiran) and a
vaccine [113,114].
Raised PCSK9 liver expression is positively linked to TNF-α and
interferon γ levels [115,116]], but no clear relationship has been ob-
served between PCSK9 levels and hsCRP. This supports the observation
that PCSK9 antagonists do not exert a significant anti-inflammatory
activity. As previously reviewed by our group [117], although there is
no impact on hsCRP, the application of this biomarker identifies pa-
tients with a high CV risk achieving better ASCVD prevention after
PCSK9 inhibition. In the FOURIER study, even in patients with ex-
tremely low levels of LDL-C, there was a stepwise risk increment ac-
cording to baseline hsCRP: +9 % (<1mg/L), +10.8 % (1–3mg/L)
and +13.1 % (>3mg/L) [118]. The ODYSSEY OUTCOMES with
alirocumab showed no absolute changes for hsCRP although baseline
hsCRP levels did identify subjects at higher risk [119]. The debate on
whether or not LDL-C and hsCRP are inseparable risk markers of risk
was addressed in a post hoc analysis of the SPIRE-1 and -2 (Studies of
PCSK9 Inhibition and the Reduction of Vascular Events) trials, with
bococizumab. This latter led to a dramatic reduction in LDL-C, but
when patients were stratified according to on-treatment hsCRP levels,
i.e.<1 (reference value), 1–3, and> 3mg/L, HRs were 1, 1.16 (95 %
Table 2
Percentage changes of hsCRP and LDL-C upon treatments with statins, ezetimibe and bempedoic acid.
Clinical study hsCRP (mg/L) LDL-C (mg/dL)
pre post Δ pre post Δ
Statins
Pravastatin [247,248] CARE 2.3 1.9 −17.4 % vs baseline 139.2 98.0 −32 % vs baseline
Pravastatin [249] PRINCE 2.4 2.0 −16.6 % vs baseline 142.9 97.5 −31.8 % vs baseline
Lovastatin [250] AFCAPS/TexCAPS 1.6 1.3 −14.8 % vs baseline 156.0 115.0 −27 % vs baseline
Atorvastatin [251,252] MIRACL 11.5 2.9 −75.0 % vs placebo 135.0 72.0 −40 % vs placebo
Pravastatin [253] REVERSAL 3.0 2.9 −5.2 % vs baseline 150.2 110.4 −25.2 % vs baseline
Atorvastatin [253] REVERSAL 3.0 1.8 −36.4 % vs baseline 150.2 78.9 −46.3 % vs baseline
Pravastatin [80,254] PROVE IT–TIMI 22 11.9 2.1 −82.4 % vs baseline 106.0 95.0 −10.4 % vs baseline
Atorvastatin [80,254] PROVE IT–TIMI 22 12.2 1.3 −89.3 % vs baseline 106.0 62.0 −41.5 % vs baseline
Simvastatin [255] A-to-Z Trial 2.01 0.17 −91.5 % vs baseline 112.0 62.0 −44.6 % vs baseline
Rosuvastatin [83] JUPITER 4.2 2.2 −47.6 % vs baseline 108.0 55.0 −49.1 % vs baseline
Simvastatin [256] Heart Protection Study 3.07 2.24 −27 % vs baseline 127.9 95.9 −25 % vs baseline
Atorvastatin [257] ASCOT 2.4 1.8 −25.8 % vs baseline 136.8 85.6 −38.7 % vs baseline
Atorvastatin [258] CARDS 1.3 1.2 −9.8 % vs baseline 121.0 60.0 −50.4 % vs baseline
Ezetimibe
Ezetimibe+ atorvastatin [259] 2.19 1.98 −10 % vs atorvastatin 101.8 89.5 −12.1 % vs atorvastatin
Ezetimibe+ rosuvastatin [260] EXPLORER 1.7 1.2 −17.8 % vs rosuvastatin 81.5 56.9 −30.2 % vs rosuvastatin
Ezetimibe+ Simvastatin [90] SHARP 1.1 0.99 −21 % vs placebo 106.0 68.9 −35 % vs placebo
Ezetimibe+ Simvastatin [89] IMPROVE-IT 1.9 1.6 −14 % vs simvastatin 67.7 49.9 −20 % vs simvastatin
Bempedoic acid
Bempedoic acid [93] CLEAR Tranquility* 2.21 1.35 −32.5 % vs baseline 129.8 96.2 −23.5 % vs baseline
Bempedoic acid [94] CLEAR Harmony*** 1.49 1.25 −14.4 % vs baseline 103.6 88.9 −12.6 % vs baseline
Bempedoic acid [95] CLEAR Wisdom** 1.61 – −24.1 % vs baseline 119.4 99.7 −12.1 % vs baseline
Bempedoic acid [96] CLER Serenity** 2.92 2.47 −25.1 % vs baseline 158.5 121.5 −21.2 % vs baseline
Bempedoic acid plus ezetimibe* [97] 3.1 – −35.1 % vs baseline 154 – −36.2 % vs baseline
hsCRP, high-sensitivity c-reactive protein; LDL-C, low-density lipoprotein cholesterol; -, not available. Adapted from [76] with permission of Taylor & Francis.
* Post= 12 weeks.
** Post= 24 weeks.
*** Post= 52 weeks.
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CI 0.81–1.66) and 1.62 (95 % CI 1.14–2.30) [120] (Table 3).
The lack of effect on hsCRP was also a common feature of inclisiran,
a small-interfering RNA (siRNA) targeting PCSK9 [117]. Recently, no
significant effects on leucocytes, monocytes or neutrophils were re-
ported, as well as no significant decrement in IL-6 (-21.3) and TNF-α
(-12.3) at the two-dose regimens of 100mg, 200mg or 300mg (at 1 and
90 days) [121].
4.7. Lomitapide
This powerful inhibitor of the microsomal transfer protein (MTP)
system was developed for the treatment of homozygous type II patients.
While clinical studies have not been addressed to the evaluation of
inflammatory/anti-inflammatory markers, of special interest is the very
long study on efficacy/safety in homozygous patients [122]. In addition
to a very effective LDL-C reduction (-45.5 %), the evaluation of data
after 246 weeks of treatment reported a moderate rise in liver fat (from
0.7 to 10.2 %) and, most interestingly, a progressive reduction of
hsCRP, with a dramatic change, i.e. -60 % from baseline to week 246.
This finding, certainly of high clinical interest, may be also linked to the
drug’s activity on the human ether-a-go-go-related gene (hERG)
channel currents, observed only at high concentrations (> 1.7 μM)
[123].
4.8. Apabetalone
Among lesser evaluated pathways underlying vascular disease and
particularly vascular calcification are the bromo- and extra-terminal
(BET) proteins (BRD2, BRD3 and BRD4). These are epigenetic readers
that bind acetylated lysines on histone tails transcription factors via
bromodomains (BD 1 and 2) [124]. BET proteins play a role as mole-
cular scaffolds between acetylation dependent binding sites and tran-
scriptional machinery. Interest in this pathway has been raised after the
observation that thienotriazolodiazepines, reportedly increasing plasma
levels of apo AI and macrophage reverse cholesterol transport in mice
[125], inhibit the BET proteins (BRTD, BRD2, BRD3 and BRD4), this
being apparently the main molecular mechanism for the apo AI change.
In view of the non-optimal activity of the thienotriazolodiazepines,
affecting essentially all BET associated proteins, a compound that has
entered clinical trial is apabetalone, preferentially targeting BRD4 and
the bromodomain BD2 [126]. Apabetalone (RVX208) has been shown
to raise HDL-C from 3.2 to 8.3 %, particularly the larger HDL particles
in humans [127].
Besides the HDL-C raising capacity, apabetalone is able to reduce
factors and pathways associated with vascular calcification, i.e. by in-
hibiting extracellular calcium deposition and reducing differentiation
markers in coronary artery vascular SMCs in osteogenic conditions
[128]. The mechanism of reduced calcification of VSMCs appears to be
a true epigenetic mechanism involving BDR4. Apabetalone also ap-
peared to reduce alkaline phosphatase (ALP) levels and also hsCRP, the
two being correlated, although reduced ALP predicted CV risk in-
dependent of hsCRP, thus possibly providing a novel mechanism of CV
protection [129].
While the numerous early studies on the CV preventive activity of
apabetalone had failed to provide convincing evidence of significant
effectiveness [130], a pooled analysis of these studies [131] had shown,
in contrast, a close to 40 % reduction of events following drug treat-
ment. This encouraged planning a secondary prevention trial in type 2
diabetics with low HDL-C (< 40mg/dL in males and<45mg/dL in
females) on optimal lipid-lowering therapy. They were randomized to
apabetalone (100mg b.i.d.) or a matching placebo [132]. After a
median follow-up of 26.5 months, 124 primary endpoints (non-fatal MI,
CV death or stroke), i.e. 10.3 %, occurred in drug-treated, vs 149 (12.4
%) in placebo-treated patients (HR 0.82: 95 % CI, 0.64–1.04). More
patients allocated to apabetalone interrupted treatment (9.4 vs 5.7 %
for the placebo group) for reasons including elevation of liver enzyme
activities. Plasma lipid and biomarker changes were of a modest degree:
there were no statistically significant differences in LDL-C levels, hsCRP
and HbA1c. At week 24, mean HDL-C levels rose from a mean of 33mg/
dL to 38.0mg/dL with apabetalone and to 36.6mg/dL with placebo
[133]. An interesting opening for apabetalone is the recently described
potential activity of BRD2 and BRD4 inhibitors on SARS-CoV-2, by way
of an interaction with transmembrane protein E of the virus [134].
5. Hypertension and inflammation
Recent developments in the understanding of CV risk associated to
hypertension have pointed out the role of novel actors in the regulation
of immune phenomena. Aside from the classical Th1 and Th2 cells,
regulatory T-cells (Tregs) and Th17 have shown differential plasticities,
indicating that in particular Tregs appear to attenuate hypertension
target organ damage, whereas Th17 cells may exacerbate damage.
Tregs are characterized by the ability to suppress inflammatory sig-
naling of immune and non-immune cells [135] and may reduce target
organ damage in hypertensive models, possibly by way of IL-10 and
TGFβ mediated immunosuppression [136]. Th17 cells are instead
characterized by the expression of transcription factor retinoic acid-
related orphan receptor (ROR)γ together with the production of IL-17.
This exacerbates tissue damage in hypertensives [137]. Tregs have been
implicated in hypertension protection experienced by females, dis-
playing, among others, a larger percentage of infiltrating T-cells in fe-
male spontaneously hypertensive rats, compared to males [138].
Inflammatory pathways and mediators are used by immune cells to
drive high blood pressure (BP) and end-organ damage. Activation of
immune cells and recruitment to a target organ leads to production of
cytokines and chemokines that determine local inflammatory re-
sponses. Inflammatory cytokines and chemokines involved in hy-
pertension are TNF-α, IL-17, MCP-1, and IL-6 [139]. Two TNF-α re-
ceptors have been described: TNFR1 and TNFR2 [140]. In humans, high
serum TNFR1 levels strongly correlate with hypertension associated
Table 3
Percentage changes of hsCRP and LDL-C upon drug treatments with PCSK9 inhibitors.
Clinical study hsCRP (mg/L) LDL-C (mg/dL)
Pre post Δ pre post Δ
Evolocumab (PCSK9 fully human
mAb)
FOURIER [118] 1.7 1.4 0 % vs placebo 92.0 30.0 −59 % vs placebo
Bococizumab (PCSK9 humanized
mAb)
SPIRE-1 and -2 [118] 1.88 1.84 at week 14: mean change was +6.6 % vs placebo
(median change 0 %); at week 52: +6.7 %
96.5 34.7 −60.5 % vs placebo
(week 14)
Alirocumab (PCSK9 fully human
mAb)
ODYSSEY OUTCOMES
[261]
1.6 (0.8-
3.9)
– – 87.0 53.0 −54.7 % vs placebo
FOURIER, Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk; SPIRE, Studies of PCSK9 Inhibition and the Reduction of
vascular Events; ODYSSEY OUTCOMES, Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab. mAb,
monoclonal antibody; -, not available.
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diseases, e.g. end-stage renal disease and type 2 diabetes [141]. There
are, however, reports indicating that genetic deletion of TNFR1 leads to
increased BP in response to angiotensin (Ang) II [142]. The epidemio-
logical Malmo Diet and Cancer Study investigated the association of
TNFR1 and TNFR2 in middle-aged individuals and reported that both
were associated with an increased risk of intracerebral hemorrhage
(ICH), suggesting that TNF mediated inflammation may lead to vascular
changes preceding ICH [143]. Studies in hypertensive patients have
shown a graded relationship of raised Intercellular adhesion molecule-1
(ICAM-1) and Vascular Cell Adhesion Molecule-1 (VCAM-1) with blood
pressure, suggestive of increased inflammatory activity in the disease
[144].
5.1. Angiotensin converting enzyme (ACE)-inhibitors
ACE-inhibitors exert a significant anti-inflammatory activity at the
vascular level. AngII treatment in rodents elevates BP and VCAM-1;
chemokines such as monocyte chemotactic protein-1 (MCP-1) and
macrophage-colony stimulating factor (M-CSF) are up-regulated in the
aortas of Ang II-treated mice. In these animals, enalapril treatment re-
duces atherosclerosis, but in particular, vascular inflammation, by
markedly reducing elevated chemokine levels [145]. A direct clinical
comparison of a major ACE-inhibitor, ramipril, with the angiotensin
receptor blocker telmisartan, in type 2 diabetics, showed that both
exerted a similar anti-inflammatory activity, as evaluated from a fall of
hsCRP [146]. The mechanisms of the proinflammatory activity of ACE
activation and its inhibition by ACE inhibitors have been extensively
investigated. ACE stimulation enhances the expression of inducible NO
synthase and COX-2 by NF-κB activation [147], also raising the pro-
duction of reactive oxygen species and of proinflammatory T cells. ACE
inhibition suppresses Th17- and Th1-mediated autoimmunity, also
promoting production of Treg, favorably modulating inflammation
[148]. Ang II may also activate the TLR4 signaling pathway, leading to
inflammatory synergism. These proinflammatory cytokines enhance
abnormal serine phosphorylation of IRS-1, thus causing insulin re-
sistance [149]. Treatment with ACE-inhibitors will rescue insulin-re-
sistance and, in some cases even cause hypoglycemia [150].
5.2. Sartans
Among sartans with apparent additional anti-inflammatory prop-
erties, telmisartan has received the largest attention. This agent can
reduce vascular SMC proliferation by a potentially additive mechanism
to angiotensin receptor blockade and PPARγ activation [151]. When
given to HIV+ patients with excess adiposity, a 40mg/day treatment
led to a significant 5 % visceral adipose tissue loss with raised urinary
excretion of prostaglandin E2. This supports the conclusion that the
anti-inflammatory activity may be linked to stimulated eicosanoid
metabolism [152]. It is of interest that candesartan, another angiotensin
receptor blocker, may reduce TLR2, TLR4 and NFkB activation in
monocytes, thus displaying a significant anti-inflammatory effect [153].
The Val-MARC study in the US compared valsartan vs valsartan/hy-
drochlorothiazide in patients with stage 2 hypertension [154]. While
the combination had a clearly better hypotensive activity vs valsartan
monotherapy, valsartan alone reduced hsCRP to a larger extent (-8.5 %)
vs the combination (+5.2 %), with modest non significantly different
lowering effects on ICAM-1 and VCAM-1 vs the combination [155],
possibly indicating a larger plaque stabilizing activity.
5.3. Calcium-channel antagonists
The therapeutic approach with calcium-channel antagonists [cal-
cium channel blockers, (CCB)] is also dependent on their anti-in-
flammatory activity at the vascular level. Ca2+ is raised at inflamma-
tion sites and activation of the calcium-sensing receptor (CaSR) may
play a pivotal role. CaSR, a cell surface coupled G protein receptor, in
the vascular area can regulate the NLRP3 inflammasome, acting by way
of Ca2+ and cAMP [156].
Significant differences can be found between the two classes of
CCBs, although neither exerts a direct anti-inflammatory activity. The
dihydropyridine CCBs, nifedipine and amlodipine, antagonize L-type
calcium channels and have antioxidant effects [157]. The rate-limiting
CCBs such as verapamil, may also improve endothelial function, in-
dicating that the benefits of these agents may be related to an improved
nitric oxide availability [158]. In gluteal resistance arteries in hy-
pertensive patients, treatment with the CCB nifedipine for 1 year im-
proved vascular relaxation responses to acetylcholine, not observed
with atenolol [159]. In the coronary vasculature, nicardipine can re-
verse endothelial dysfunction in non-stenotic segments from hy-
pertensive patients and in stenotic segments from both normotensives
and hypertensives [160]. Nicardipine has been shown to improve en-
dothelium-dependent vasodilation in patients with essential hyperten-
sion [161] and to raise coronary vascular responses to acetylcholine.
Amlodipine increases basal NO release, whereas lacidipine enhanced
the vasodilator responses to both acetylcholine and bradykinin within
the forearm circulation of hypertensive patients [162].
6. Diabetes and inflammation
The pattern of pathological responses characteristic of type 2 dia-
betes is dependent on the sensitivity of vessels to oxidative stress, hy-
pertension, dyslipidemia and aging, all determining the risk of ather-
osclerosis progression and regression. In diabetes, endothelial cell
dysfunction is of frequent occurrence [163]. It is characterized by
raised production of cytokines and adhesion molecules: altogether they
initiate the inflammatory driven responses including leukocyte re-
cruitment and platelet activation. Characteristic of diabetes is, in par-
ticular, the activation of the proteolytic enzymes known as matrix
metalloproteinases (MMPs). MMP activity is regulated by the en-
dogenous tissue inhibitor of metalloproteinases (TIMP). MMPs mediate
the retinal neuropathy and vasculopathy that are associated with dia-
betes [164].
Hyperglycemia and elevated FFAs may promote inflammation by
stimulating glucose utilization with altered oxidative phosphorylation.
This will induce a proinflammatory trait in macrophages in the adipose
tissue and other tissues, including the vasculature [165]. Glucotoxicity
and lipotoxicity, by exerting oxidative and endoplasmic reticulum
stress, elicit an inflammatory response by activating thioredoxin in-
teracting proteins (TXNP and NLR families) including NLRP3. This
latter stimulates the release of mature IL1-β [166] which further am-
plifies inflammation by recruiting immune cells including macrophages
[167].
Among the molecular mechanisms underlying diabetes related in-
flammation is the reduction of fatty acid synthase (FAS). FAS, a large
molecule producing mainly palmitate, as well as other mainly saturated
FFAs, is reduced in many tissues in diabetic models. Liver specific in-
activation of FAS leads to fatty liver, hypoglycemia and enhanced in-
sulin sensitivity, a picture not different from models of the deficiency of
the nuclear receptor PPARα [168]. FAS deficiency, in contrast, leads to
protection from insulin resistance and with disrupted function of
Cdc42, a member the RhoGTPase family, coordinating macrophage
activation in target tissues [169]. Reduced activation is associated with
altered phospholipid and protein composition, responsible for the in-
flammatory signaling coordinated by RhoGTPase. These findings have
contributed to the understanding of the role of cholesterol in the in-
flammatory induction. FAS is required for the assembly of cholesterol
and sphingomyelin in the plasma membranes of macrophages [170].
Membrane phospholipids control clustering of domains required for
signaling such as in dendritic cell activation [171], Th-17 helper cell
differentiation [172] and other mechanism of activation of inflamma-
somes in macrophages. FAS inhibition thus may lead to reduced
atherosclerosis, less adiposity and reduced blood glucose in skeletal
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muscle. This basic knowledge allows the evaluation of potential links
between inflammation and antidiabetic drugs, active not only on glu-
cose, but also on different steps in the diabetes related inflammatory
process.
6.1. Metformin
This compound is the most widely used glucose lowering drug,
whose effects are believed to be mediated by activation of AMPK, a key
regulator of energy homeostasis [173]. Metformin directly inhibits the
production of reactive oxygen species from complex I (NADH: ubiqui-
none oxido-reductase) of the mitochondrial electron transport chain.
Metformin inhibits the pro-form of the IL-1β in lipopolysaccharide
(LPS) activated macrophages while stimulating induction of the anti-
inflammatory cytokine IL-10 [174].
In the vascular endothelium, metformin inhibits monocyte-to-mac-
rophage differentiation [175]. While these effects in rodents are well
established, in particular by reducing the proinflammatory and proa-
poptotic protein TXNIP in β-cells and hepatocytes [176], data in hu-
mans are not well clarified. Metformin appeared to reduce hsCRP to a
modest extent in patients in the US Diabetes Prevention Program [177].
In the LANCET Trial (Long acting Insulin Injections to Reduce C-Re-
active Protein in Patients with Type 2 Diabetes), metformin did not
modify inflammatory markers in patients with recent onset type 2
diabetes [178]. In recent years, exciting news have been provided on
the potential beneficial effects of metformin in chronic inflammatory
disorders and cancer, also extending lifespan independent of glucose
metabolism [179].
6.2. Sulphonylureas and thiazolidinediones
While losing clinical interest because of their high potential to in-
duce hypoglycemia, sulphonylureas have been shown to exert poten-
tially significant anti-inflammatory effects. Glyburide appears to inhibit
the NLRP3 inflammasome and the subsequent IL-1β activation in
macrophages [180]. Gliclazide seems to exert a similar effect, i.e. re-
duced endothelial dysfunction in type 2 diabetes patients [181]. In
clinical trials, however, sulphonylureas did not appear to exert a sig-
nificant influence on hsCRP levels, whereas reductions were found after
treatment with the thiazolidinediones (TZDs) [182].
TZDs are PPARγ agonists that increase insulin sensitivity. There is
experimental evidence that PPARγ and AMPK are both targets of TZD
with consequent significant anti-inflammatory effects in liver and adi-
pose tissue [183]. Pioglitazone treatment may thus reduce infiltration
of adipose tissue by proinflammatory macrophages, leading to im-
proved hepatic and peripheral insulin sensitivity, potentially exerting
an ameliorating effect on liver histology in patients with nonalcoholic
steatohepatitis (NASH) [184].
Treatment with TZDs, in addition to improving endothelial func-
tion, can significant reduce hsCRP levels in people with and without
diabetes irrespective of glycemic effects [185]. The apparent anti-in-
flammatory activity of PPARγ agonists may be possibly related to the
novel observation of their interaction with NLRC5, inhibiting vascular
neointima formation [22]. The reduced hsCRP and increased HDL-C
after pioglitazone treatment may explain the observed consequent re-
duction in CV morbidity [186].
6.3. Incretins and incretin drugs
Incretin drugs are a new widely used group of glucose lowering
agents which antagonize glucagon secretion and delay gastric emp-
tying. Two groups of incretin hormones, the glucagon-like peptide-1
(GLP-1) and the glucose-dependent insulinotropic polypeptide (GIP)
stimulate insulin secretion in a glucose-dependent manner and, in the
case of GIP, reduce gastric acid secretion. Incretin hormone secretion
can be activated by inflammatory mediators such as IL-6 and IL-1β
[187]. The rapid degradation of GLP-1 and GIP by dipeptidyl peptidase-
4 (DPP-IV) has led to the development of two new classes of incretin-
based drugs, i.e. GLP-1R agonists and DPP-IV inhibitors [188]. GLP-1R
agonists include liraglutide, exenatide, lixisenatide and albiglutide;
DPP-IV inhibitors target degradation systems of incretin hormones and
include sitagliptin, vildagliptin, saxagliptin, linagliptin and alogliptin
[189]. These agents are listed in the European Society of Cardiology
(ESC) and the European Association for the Study of Diabetes (EASD)
Guidelines [190].
Both drug classes have given substantial evidence of improving a
variety of CV risk factors as well as inflammation. In particular DPP-IV
inhibitors can suppress NLRP3, TLR4 and IL-1β expression in macro-
phages [191]. They can also reduce mRNA expression of CD26, TNF-α,
proinflammatory kinases, and chemokine receptor CCR2, as well as
plasma hsCRP, IL-6 and FFA [192]. In a clinical study evaluating en-
dothelial dysfunction and inflammation in patients with type 2 diabetes
treated with sitagliptin, there was clear evidence of reduced levels of
markers including hsCRP, L-6, IL-1β phospholipase-A2, ICAM-1 and E
selectin [193].
The case of GLP-1R agonists (GLP-1RAs) has provided somewhat
similar findings in the lipid profile but also in statistically significant
reductions of markers including hsCRP, brain natriuretic peptide and
PAI-1 [194]. Balestrieri et al. tested the anti-inflammatory activity in
diabetic atherosclerotic plaques, reporting that plaques from incretin-
treated type 2 diabetic patients are characterized by increased collagen
content, raised sirtuin-6 expression and inhibited inflammatory re-
sponse with reduced numbers of macrophages, T cells and lower ex-
pression of MMP-9 and TNFα [195].
Incretin drugs, particularly GLP-1RAs, although effective on gly-
cemia and well tolerated, have not generally provided consistent re-
ductions in CV events. In the case of DPP-4 inhibitors outcome trials,
the three-point MACE evaluation of the LEADER (Liraglutide Effect and
Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial
reported significant reductions of events at all ages with somewhat
reduced efficacy in individuals ≥ 60y [196]. The SUSTAIN trial with
semaglutide with a similar design again resulted in a significant re-
duction of three-point MACEs with no differences between younger and
older patients [197].
6.4. Sodium glucose cotransporter 2 inhibitors (SLGT2)
In all clinical trials, SGLT2 have consistently shown a CV benefit,
both in younger and older individuals. Very interestingly, in the case of
empagliflozin (EMPA-REG Trial) and canagliflozin (CANVAS Trial)
[198,199], CV event reduction was not only of the ischemic type but,
more frequently, consequent to reduced heart failure. These impressive
results on heart failure are the object of intensive investigation and the
recently completed DECLARE TIMI 58 with dapagliflozin confirmed the
improvement of the heart failure endpoint but no clear benefit on
MACE endpoints [200].
The significant reduction in hospitalizations for heart failure and
progression of renal disease have not found a clear support from
changes in the inflammatory profile in earlier studies with the SGLT
inhibitor phlorizin in obese gerbils. In these, a decrement in islet in-
flammation, possibly related to reduced glucose toxicity, was detected
[201]. Similarly, in mice with type 2 diabetes, the SGLT2 inhibitor
empaglifozin, in addition to positive changes in hyperglycemia and
hyperlipidemia, reduced markers of inflammation (IL-6, TNF-α, MCP-1
and CRP levels) [202]. In the same experimental model, no data on
inflammation were reported with canagliflozin [203].
Although data of this type have not been made available in the
cardiovascular outcome trials with canagliflozin, 12 months of treat-
ment with empagliflozin decreased hsCRP (-43 %) and lowered levels of
remnant related lipoproteins probably via ameliorating insulin re-
sistance [Hattori, 2018 #402].
The DECLARE TIMI 58 study [200] with dapagliflozin did not
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provide data on inflammation. While expecting clinical data from the
CREDENCE Study with canagliflozin [205], attempting to establish
inflammatory biomarker changes, a number of exploratory data have
been provided with SLGT2 inhibitors mainly on short-term evaluations.
Reduction in leptin levels and increased adiponectin are generally re-
ported, as well as modest reductions in hsCRP TNF-α, IL-6 and IFNγ
with canagliflozin, dapagliflozin and empaglifozin, mainly not reaching
statistical significance [204]. In the CANTATA-SU Study [206], with
canagliflozin, there was a 22 % reduction of IL-6 and a slight reduction
of hsCRP (-4.4 %). Conversely, a 7 % increase in TNF-α was detected
after canagliflozin vs glimepiride (Table 4). Overall the effects on in-
flammatory markers are very modest and probably not contributing to
the CV outcomes.
7. Microbiome and inflammation
The trillions of microbes colonizing the human intestinal tract are of
major importance for human development and physiology [207]. Al-
terations of the microbiome, however, may be associated with multiple
disorders including a raised prevalence of atherosclerotic diseases
[208]. Among the best-studied mechanisms underlying this association
is the increase of circulating trimethylamine oxide (TMAO) derived
from the metabolism of choline and carnitine by the gut microbiome
[209]. More recently the same authors indicated that the TMAO pre-
cursor trimethylysine is also associated with adverse cardiac risk and
the two together provide the best risk estimate [210]. Contrasting data
have been reported in an animal model: in the apoE−/− mice, Collins
et al. [211] found that carnitine fed animals have raised TMAO levels
but these are inversely related to aortic lesion formation. In the same
model, mice fed chow or Western diet and low or no choline supple-
ment showed raised plasma TMAO levels in the latter group in con-
ventional (not germ free) mice [212]. Choline treatment did not affect
aortic lesion size or plasma cholesterol and there was no difference in
glycoprotein CD68 in macrophages. Similarly, no clear inflammatory
related responses of microbiota to choline could be found, following
evaluation of 10 cytokines in plasma from apo E-/- mice. There is,
however, clear evidence for a wide dispersion of baseline data in the
clinical studies [213]. In order to improve prediction, very recently
Cassambai et al [214] suggested a choline loading test (700mg oral
choline bitartrate) followed by oral determinations for 8 h, indeed
showing clear interindividual differences.
There are limited data on the direct effect of microbial changes on,
particularly, endothelial function and the endothelial inflammatory
phenotype. Limited information in rodent models has indicated that a
Table 4
Changes of inflammatory biomarkers upon drug treatments with SGLT-2 inhibitors.
Clinical study IL-6 hsCRP TNF-α
Canagliflozin [262] CANTATA-SU −22 % −4.4 % +7 %
Empagliflozin [263] Patients with a history of medication with SGLT2 inhibitors – −54 % –
Dapagliflozin [264] Patients with Nonalcoholic Steatohepatitis – From 0.26 (0.11-0-53) to 0.14 (0.08-0.26); p < 0.001 (after 4 weeks) –
SGLT-2, Sodium Glucose Cotransporter 2 Inhibitors; -, not available.
Fig. 2. Anti-inflammatory effects of lipid lowering drugs. The NLRP3 inflammasome system induces the activation of caspase-1 which, in turn, cleaves pro-IL-1β and pro-
IL-18 to their active counterparts that induce IL-6. In the liver, IL-6 induces CRP, a clinically proven biomarker of inflammatory status and cardiovascular risk. The
evaluation of high sensitivity CRP (hsCRP) levels identifies patients with low (<1mg/L), intermediate (1–3mg/L) and high (> 3mg/L) risk. Several lipid lowering
drugs reduce hsCRP levels, including the HMG-CoA reductase inhibitors (statins), ATP citrate lyase inhibitor (bempedoic acid), the PPARα agonists (fibrates), and the
MTP inhibitor lomitapide. The NPC1L1 inhibitor, ezetimibe, reduces cholesterol absorption and hsCRP levels, similar to nicotinic acid, acting mainly in the adipose
tissue by reducing lipolysis.
CRP, C-reactive protein; NLRP3, NACHT-, LRR- and pyrin domain-containing 3; ASC, apoptosis-associated speck-like protein containing a CARD; FFA, Free-fatty
acids; MTP, microsomal transfer protein; NPC1L1, Niemann-Pick C1-Like 1; PPAR, Peroxisome proliferator-activated receptor gamma.
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major probiotic, Lactobacillus plantarum, may reduce myocardial infarct
size in hypertensive rats [215], as well as suppress LPS-mediated
atherosclerotic plaque inflammation [216]. The potential of Lactoba-
cillus plantarum 299v (Ly299v) was evaluated by Malik et al [217] that
directly tested in ASCVD patients the effects of oral Lp299v (20 billion-
colony forming units (CFU) qd) for 6 weeks. Treatment did not change
lipids, glucose or BMI, but improved flow-mediated dilation. While
TMAO levels were unchanged, significant reductions of IL-8 and IL-12
were recorded. Resistance arteries isolated from patients after treat-
ment and exposed to postbiotic plasma showed raised endothelium-
dependent vasodilation.
The positive results of this last study suggested the experimental
evaluation in a more frequent case of inflammation-mediated en-
dothelial dysfunction and arterial stiffening, i.e. aging [218]. These
Authors, by suppressing gut microbiota with antibiotic treatment in old
mice noted reversed endothelial dysfunction and arterial stiffening,
with attenuated vascular oxidative stress and inflammation. Plasma
levels of TMAO were also suppressed by antibiotic treatment. The Au-
thors noted an increase of the phylum Proteobacteria in antibiotic
treated mice, almost entirely attributable to unclassified species within
the Enterobacteriaceae. The issue of proinflammatory gut microbiota
was examined by the use of caspase 1−/− mice with proinflammatory
microbiota in LDLr−/− mice [219]. When proinflammatory casp1−/−
microbiota was introduced into LDLr−/− mice a remarkable increase of
systemic inflammation and atherogenesis was reported.
The aim of identifying enteral bacteria, possibly responsible for
reducing inflammation and improving endothelial function, has called
attention to the Akkermansia muciniphila, an enteral commensal anae-
robe, postulated to exert potential anti-obesity effects, linked to re-
duced insulin-resistance [220]. Interestingly, beneficial properties ap-
pear to be improved by pasteurization [221]. Three-month
supplementation of pasteurized A. muciniphila (1010 CFU daily) in in-
sulin resistant volunteers reduced circulating LPS endotoxemia and
white blood cells [222]. These findings support the hypothesis, now
held by several Authors, that probiotic treatment with live bacteria may
improve barrier function in the intestine, thus ameliorating both me-
tabolic parameters as well inflammation [223]. It may lead to improved
vascular function in aging and vascular disease.
8. Nutraceuticals
Diet, the most common variable for all individuals, may influence
inflammation, in particular vascular inflammation, to a different extent
according to general components, as well as to components with a drug-
like activity, among these unsaturated fatty acids and commonly used
nutraceuticals.
8.1. Omega- 6 fatty acids
Omega-6 fatty acids are a major component of the daily lipid intake.
The most represented polyunsaturated fatty acid (PUFA) is linoleic acid
(LA:18:2 n-6). A most recent assessment of omega-6 PUFA intake
among adults in the UK was 10.9 ± 4.7 g/day, most of which (at least
90 %) would be LA, responsible for about 7 % of daily energy. LA is
Fig. 3. Anti-inflammatory effects of antidiabetic drugs. In the vascular endothelium, metformin inhibits monocyte-to-macrophage differentiation. TZDs are PPARγ
agonists inhibiting vascular neointima formation. In mice with type 2 diabetes, the SGLT2 inhibitor may reduce IL-6, TNF-α, MCP-1 and CRP levels. GLP-1 agonists
and DPP-IV inhibitors can reduce NLRP3, TLR4, IL-1β and PAI-1 expression in plaques and macrophages.
DDP IV: dipeptidyl peptidase-4; SGLT2: Sodium Glucose Cotransporter 2 Inhibitors; GLP1: glucagon-like peptide-1; TDZ: thiazolidinediones; PPARγ: Peroxisome
proliferator-activated receptor gamma; PAI-1: Plasminogen activator inhibitor-1.
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converted after a series of steps to γ-linolenic acid, dihomo-γ-linolenic
acid and arachidonic acid (ARA) [224]. This last is the major precursor
of eicosanoids, being converted by cyclooxygenase-1 (COX-1) to pros-
taglandins/thromboxanes. Concentrations of ARA-derived eicosanoids
are elevated in inflammatory conditions. Pathways to ARA synthesis
from LA is generally saturated in the presence of a high LA intake in
humans (likely to be around 10 g/d) and thus raised LA intake will have
no further effect in promoting ARA synthesis. This generally leads to
unchanged levels of ARA in circulating mononuclear cells (MCs), and it
is unlikely to see much of a change in inflammatory markers following
raised dietary LA in individuals on a normal diet [225].
The major potential effect of LA itself on inflammation is its meta-
bolism to lipoxygenase (LOX) derivatives such as the hydro-
xydecadienoic acids (HODEs) and further to oxo-HODEs and epoxy-
HODEs, playing a role in inflammation and having been detected in
colonic mucosal biopsies of patients with ulcerative colitis without,
however, being significantly related to the degree of inflammation
[226]. Dietary LA intake was not associated with the inflammatory
markers CRP, IL-6, soluble (s)TNF-R and sTNF-R2 [227,228]. Despite a
long-held belief, available evidence does not support the conclusion
that a high dietary intake or high plasma LA concentrations raise tissue
ARA or change inflammatory marker concentrations in humans.
The lack of a significant anti-inflammatory effect of LA or in general
omega-6 fatty acids in spite of the beneficial activity on CV prevention
is well supported by the very recent novel Consortium Evaluation of 30
prospective observational studies from 13 countries (follow up ranging
between 2.5 to 31.9 years) [229]. High LA levels were associated with a
lower risk of total CVD, CV mortality and ischemic stroke, with ratios
between 0.93 and 0.88. ARA levels were instead not associated with a
high risk of CV outcomes. Paradoxically, in extreme quintiles, higher
ARA levels were linked to a lower risk of total CVD, thus supporting in
general a favorable role for LA in CVD prevention.
8.2. Omega-3 fatty acids
Dietary intake of omega-3 fatty acids is essential for health, since
these PUFAs cannot be synthesized to a significant extent. Omega-3
PUFAs are regarded as anti-inflammatory, exerting their effects via
multiple mechanisms [230]. These include the partial inhibition of a
number of steps of inflammation such as leukocyte chemotaxis, pro-
duction of inflammatory cytokines, adhesion molecule expression,
leukocyte-endothelial adhesive interactions, and Th1 lymphocyte re-
activity [231]. From the results of a number of randomized controlled
trials, the anti-inflammatory effect of omega-3 PUFA was associated to
a reduction of hsCRP, IL-6 and TNF [232]. The basic mechanism is the
incorporation of EPA and docosahexaenoic acid (DHA) into cell mem-
branes at the expense of ARA, resulting in inhibited ARA metabolism
and consequent decreased expression of the COX gene and, as a final
consequence, reduction of ARA derived eicosanoids.
More recently, a major advance in the field of PUFA and in-
flammation has been the discovery of the so called pro-resolving lipid
mediators. These mediators include resolvins from EPA (E-series) and
DHA (D-series) and protectin and maresin from DHA. Their synthesis
involves the COX and LOX pathways operating in a transcellular
manner [233]. These compounds can be found in humans after EPA or
DHA intake [234] and have shown anti-inflammatory benefits in vitro
and in animal models of inflammation [235]. By these mechanisms,
omega-3 PUFA and especially DHA decrease expression of adhesion
molecules such as ICAM-1 on the surface of endothelial cells and
monocyte cultures, as well as of macrophage scavenger receptor A in
rats fed a high fat fish oil diet [236].
The activity on NF-κB is probably exerted by reduced translocation
of the NF-κB p503 and p-65 subunits to the nucleus where they bind
omega-3 response elements, upregulating inflammatory gene expres-
sion. Exposure of macrophages to DHA inhibits the TLR4 agonist (LPS)
ability to promote recruitment of co-stimulatory molecules, MHC class
II and to stimulate cytokine production [237].
In view of the relatively simple way of measuring circulating
proinflammatory cytokines, a randomized controlled study in aging
adults with chronic venous leg ulcers given EPA+DHA therapy (2.5 g/
d) reported reductions in IL-6, IL-1β and TNF-α after 4 and 8 weeks of
treatment [238]. A direct evaluation of the two fatty acids was carried
out by Allaire et al. [239], testing in a double-blind fashion supple-
mentation of EPA vs DHA (both 2.7 g/d) and corn oil for periods of 10
weeks. Compared to EPA, DHA led to a larger reduction of IL-1β, in-
creased adiponectin and reduction of hsCRP (-7.9 vs -1.8 %) and TNF-
α (-14.8 vs -7.6 %); effects on IL-6 (-12.0 vs -13. 4 %) were similar. Fish
oil can also reduce the inflammatory effects of TMAO, as recently
shown in apoE−/− mice fed a Western diet and additional TMAO
[240]. Fish oil fed animals had significantly reduced atherogenesis
(compared to animals fed flaxseed oil) with marked reduction of in-
flammatory markers.
All these findings have become of great interest after the positive
outcome of the REDUCE-IT study on high dose EPA given to secondary
prevention patients with elevated triglyceridemia [241]. In this study
patients received 2 g bid of purified EPA vs placebo, resulting in a
primary endpoint reduction of 25 % [242]. Interestingly, at the last
visit, hsCRP levels were reduced by 23 %, thus probably adding to the
CV benefit of EPA intake.
9. Conclusions
The clinician’s approach to arterial disease is more and more fre-
quently calling to action on an inflammatory condition and on the
potential use of agents affecting inflammation [243]. This latter is
certainly consequent to the presence of cholesterol crystals in the le-
sion, promoting plaque instability, but newer factors have come into
play, in particular from an improved knowledge of myelopoiesis related
mechanisms [9]. Both raised progenitor cell recruitment after major CV
events and clonal hematopoiesis related mechanisms, have provided
crucial information on the inflammatory mechanisms underlying the
ACS, also identifying potentially protective mechanisms such as the
TET2 production [19] (Graphical abstract).
Clinical diagnostics in CVD has instead mainly relied on circulating
biomarkers, in particular the hsCRP, working as an acute marker and as
an event predictor. Agents affecting hsCRP levels, in particular cana-
kinumab and, more recently, colchicine, both reduced hsCRP and in-
flammatory phenomena, leading to a reduced number of event relapses,
independent of changes of other risk markers including lipids or hy-
pertension [57,63,68].
Among drug classes of common use in CVD treatment, variable ef-
fects have been shown on inflammatory biomarkers, in particular
hsCRP [244]. In the case of lipid lowering agents, statins have provided
the first evidence indicative of the CV benefit of the reduction of hsCRP
in addition to that of LDL-C [245]. Fibrates have shown hsCRP reduc-
tion in the metabolic syndrome, whereas ezetimibe has modest effects,
potentially additive to those of statins in drug combinations. Finally,
among newer agents, bempedoic acid appears to provide the best
combination of LDL-C and hsCRP reductions. The case of PCSK9 an-
tagonists is more complex, since these agents do not directly reduce
hsCRP levels [246]. However, identification of patients with elevated
hsCRP leads to the choice of individuals best responding to drug
treatment [117] (Fig. 2).
Among agents for blood pressure lowering, ACE inhibitors have an
optimal anti-inflammatory activity, potentially additive to that of sar-
tans, somewhat less effective but exerting a stimulatory activity on ei-
cosanoid metabolism. Calcium channel blocker act by way of a CaSR, a
cell surface coupled G protein receptor, regulating the NLRP3 in-
flammasome in the vascular area.
The diabetic condition is characterized by an increased in-
flammatory burden, with endothelial cell dysfunction and increased
adhesion molecules. The novel antidiabetic agents, such as the incretin
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drugs, antagonizing glucagon secretion and delaying gastric emptying,
reduce inflammatory mediators, including hsCRP, IL-6, IL1-β and
ICAM-1. The SLGT-2 inhibitors, instead, have in general shown im-
pressive CV benefit, reduction of events being not only of the ischemic
type but more frequently consequent to heart failure. This impressive
clinical activity has, however, been associated with modest reductions
in hsCRP, TNF-α, and IL-6, thus suggesting that the anti-failure activity
may not be linked to an anti-inflammatory effect (Fig. 3).
Novel findings on the microbiome have pointed to the proin-
flammatory activity of the metabolite TMAO, resulting from the me-
tabolism of choline/carnitine by the gut microbiome. This circulating
product leads to raised inflammatory and atherosclerotic risk in animal
models, associated with an enhanced clinical risk of coronary disease.
Opposite effects can have microbial changes such as those occurring
with major probiotic, Lactobacillus plantarum, reducing myocardial in-
farction in hypertensive animals as well as suppressing LPS-mediated
atherosclerotic plaque inflammation. A clinical study indicated an ef-
fective preventive activity of the oral administration of a Lactobacillus
plantarum strain. This led to the investigation to the most frequent in-
flammation mediated endothelial dysfunction and arterial stiffening,
i.e. aging. Suppression of microbiota in old mice can reverse endothelial
dysfunction and the accompanying vascular oxidative stress and in-
flammation. Enterobacteriaceae may play a crucial role in atherogen-
esis induction and prevention in old age and identification of the re-
sponsible strains has become a major topic of research, the most
attractive mechanism being that of improving barrier function in the
intestine, thus ameliorating metabolic parameters and inflammation.
Dietary components, in particular unsaturated fatty acids and other
nutraceuticals from the plant kingdom, have provided exciting results
in the reduction of CV diseases and inflammation. While omega-6 fatty
acids, aside from their lipid lowering properties, do not seem to exert
clear anti-inflammatory activities, omega-3 fatty acids have provided
very important findings in the prevention of CV disease, such as in the
REDUCE-IT trial with high dose EPA. Aside from the so called pro-re-
solving lipid mediators, i.e. resolvins, protectins and maresin, the clear
anti-inflammatory activity of both EPA and DHA has provided sig-
nificant benefit, reducing proinflammatory cytokines and hsCRP.
The overall evaluation of present knowledge on inflammation and
CV risk points out, to specialists and non-specialists, the major role of
evaluating the pro- and antiinflammatory profile of major agents used
in therapy as well as the diagnostic criteria for establishing the most
appropriate guidelines for prevention and treatment.
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